Related Experiment Video

Updated: Jan 28, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future

Faiez Zannad1, João Pedro Ferreira1,2, Bertram Pitt3

  • 1Université de Lorraine INSERM, Centre, d'Investigations Cliniques Plurithématique 1433, INSERM U1116, CHRU de Nancy, F-CRIN INI-CRCT, France.

European Heart Journal Supplements : Journal of the European Society of Cardiology
|March 7, 2019
PubMed

Insights

New potassium binders may help manage hyperkalemia, allowing crucial cardiovascular drug use. However, their proven benefit on patient outcomes requires further research before widespread recommendation.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular medications can increase serum potassium levels, posing a risk to patients.
  • Hyperkalemia necessitates dose reduction or discontinuation of beneficial cardiovascular therapies.
  • Potassium binders offer a potential solution to manage hyperkalemia during cardiovascular treatment.

Purpose of the Study:

  • To review the current evidence on potassium binders for hyperkalemia management.
  • To evaluate the potential clinical applications of potassium binders.
  • To identify future research directions for potassium binders in cardiovascular care.

Main Methods:

  • Comprehensive literature search on potassium binders and hyperkalemia.
  • Analysis of preclinical and clinical studies on potassium binder efficacy and safety.
  • Review of guidelines and expert opinions regarding potassium binder use.

Main Results:

  • Potassium binders demonstrate efficacy in reducing serum potassium levels.
  • The direct impact of potassium binders on cardiovascular event reduction remains under investigation.
  • Further clinical trials are needed to establish a causal link between binder use and improved patient prognosis.

Conclusions:

  • Potassium binders represent a promising therapeutic strategy for managing hyperkalemia.
  • Evidence supporting the improvement of patient prognosis with potassium binders is currently limited.
  • Future research should focus on long-term outcomes and clinical benefits in cardiovascular populations.

Keywords:
OutcomesPotassium bindersTrials

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.4K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
829
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
855
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
935
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
267
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
313